## Benjamin A Derman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4344527/publications.pdf

Version: 2024-02-01

34 609 11 24
papers citations h-index g-index

34 34 34 1111 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Knowing the unknowns in high risk multiple myeloma. Blood Reviews, 2022, 51, 100887.	5.7	6
2	Moving Toward a Cure in Multiple Myeloma: Eradication of Measurable Residual Disease. Advances in Oncology, 2022, 2, 159-169.	0.2	0
3	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. , 2022, $10$ , e004766.		11
4	Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. Blood Cancer Journal, 2022, 12, .	6.2	1
5	Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e1000-e1008.	0.4	1
6	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	7.2	69
7	Sex differences in outcomes in multiple myeloma. British Journal of Haematology, 2021, 192, e66-e69.	2.5	12
8	Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program. JCO Oncology Practice, 2021, 17, e445-e453.	2.9	10
9	Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer Journal, 2021, 11, 19.	6.2	40
10	Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. Journal of Geriatric Oncology, 2021, 12, 585-591.	1.0	10
11	Efficacy and tolerability of a modified pediatricâ€inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem, 2021, 2, 413-420.	1.0	4
12	Recommendations for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy. JAMA - Journal of the American Medical Association, 2021, 326, 1058.	7.4	13
13	ATTR Cardiomyopathy Meets MultipleÂMyeloma. JACC: CardioOncology, 2021, 3, 598-601.	4.0	2
14	Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 614-622.	1.3	29
15	Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement. Blood Advances, 2020, 4, 4924-4928.	5.2	12
16	Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer Journal, 2020, 10, 80.	6.2	35
17	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood, 2020, 136, 2513-2523.	1.4	56
18	Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Advances, 2020, 4, 2810-2820.	5.2	47

#	Article	IF	Citations
19	Clinician attitudes and practices toward measurable residual disease in multiple myeloma. British Journal of Haematology, 2020, 190, 470-472.	2.5	1
20	Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study., 2020, 8, e000286.		11
21	Real-World Validity of the Revised International Staging System in Multiple Myeloma By Race. Blood, 2020, 136, 40-41.	1.4	0
22	Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?. Best Practice and Research in Clinical Haematology, 2019, 32, 101102.	1.7	6
23	Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Advances, 2019, 3, 3488-3498.	5.2	62
24	Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study. Blood, 2019, 134, 4606-4606.	1.4	5
25	Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma. International Journal of Nephrology, 2018, 2018, 1-6.	1.3	5
26	Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer, 2017, 17, 141.	2.6	53
27	Bendamustine-induced nephrogenic diabetes insipidus. Clinical Nephrology, 2017, 87, 47-50.	0.7	4
28	Disparities in Renal Recovery Between African Americans Vs. Non African Americans Following Initial Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Chart Review. Blood, 2016, 128, 5610-5610.	1.4	0
29	Nitric Oxide, Coagulation and Cancer. , 2015, , 281-295.		0
30	Risk Factors, Diagnosis, Management, and Outcome of Splanchnic Vein Thrombosis: A Retrospective Analysis. Seminars in Thrombosis and Hemostasis, 2015, 41, 503-513.	2.7	23
31	Treatment of advanced squamous cell carcinoma of the lung: a review. Translational Lung Cancer Research, 2015, 4, 524-32.	2.8	74
32	A small field for fertile science: the low visibility of reproductive science in high impact journals. Journal of Assisted Reproduction and Genetics, 2014, 31, 511-520.	2.5	4
33	Breast cancer in postmenopausal women after non-melanomatous skin cancer: the Women's Health Initiative observational study. Breast Cancer Research and Treatment, 2013, 139, 821-831.	2.5	3
34	Risk Factors, Diagnosis, Management, and Outcomes For Splanchnic Vein Thrombosis: A Retrospective Analysis. Blood, 2013, 122, 2372-2372.	1.4	0